Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT04222972 Active, not recruiting - Neoplasms Clinical Trials

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

AcceleRET-Lung
Start date: July 24, 2020
Phase: Phase 3
Study type: Interventional

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.

NCT ID: NCT04221893 Recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Start date: August 7, 2020
Phase: N/A
Study type: Interventional

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

NCT ID: NCT04221828 Terminated - Prostate Cancer Clinical Trials

Trial of NanoPac Focal Therapy for Prostate Cancer

Start date: October 20, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.

NCT ID: NCT04221555 Recruiting - Clinical trials for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: May 13, 2020
Phase: Phase 2
Study type: Interventional

Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinoma

NCT ID: NCT04220827 Active, not recruiting - Clinical trials for Peritoneal Carcinomatosis

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Start date: December 6, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT04219137 Recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

MOCHA
Start date: November 14, 2019
Phase:
Study type: Observational

Researchers are looking to further our knowledge on disease biology and treatment selection for gastroesophageal adenocarcinoma. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients for the future.

NCT ID: NCT04216758 Recruiting - Clinical trials for Stage IB Pancreatic Adenocarcinoma

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant chemotherapy after radical resection of pancreatic cancer

NCT ID: NCT04209686 Recruiting - Clinical trials for Advanced Gastric Adenocarcinoma

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Start date: July 31, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

NCT ID: NCT04208958 Completed - Colorectal Cancer Clinical Trials

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

ConsortiumIO
Start date: January 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer

NCT ID: NCT04208347 Active, not recruiting - Clinical trials for Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Start date: December 18, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.